5- [4- (2-Carboxyethylcarbamoyl)-phenylazo]-salicylic acid disodium salt dihydrate (BX661A)

Folia Pharmacologica Japonica

Volumn 109, Issue 2, 1997, Pages 85-94

  Kimura, Isami ^a   Nagahama, Shinobu ^a   Kawasaki, Maki ^a   Kataoka, Mikiko ^a   Sato, Makoto ^a  

^a SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

4 (2 ANTHRYL)BUTYRIC ACID; 4-(2-ANTHRYL)BUTANOIC ACID; AMINOSALICYLIC ACID DERIVATIVE; ANTHRACENE DERIVATIVE; ANTIULCER AGENT; BALSALAZIDE; DEXTRAN SULFATE; MESALAZINE; NONSTEROID ANTIINFLAMMATORY AGENT; PHENYLHYDRAZINE DERIVATIVE; SALAZOSULFAPYRIDINE; SULFAPYRIDINE;

ANIMAL; ARTICLE; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; MALE; ORAL DRUG ADMINISTRATION; RAT; SPRAGUE DAWLEY RAT; ULCERATIVE COLITIS;

ADMINISTRATION, ORAL; AMINOSALICYLIC ACIDS; ANIMALS; ANTHRACENES; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTI-ULCER AGENTS; COLITIS, ULCERATIVE; DEXTRAN SULFATE; MALE; MESALAMINE; PHENYLHYDRAZINES; RATS; RATS, SPRAGUE-DAWLEY; SULFAPYRIDINE; SULFASALAZINE;

EID: 0345111338     PISSN: 00155691     EISSN: None     Source Type: Journal    
DOI: 10.1254/fpj.109.85     Document Type: Article

References (27)

1. Azad Khan AK, Piris J and Truelove SC: An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet II 29, 892-895 (1977)
2. Van Hees PAM, Bakker JH and Van Tongeren JHM: Effects of sulphapyridine, 5-aminosalicylic acid and placebo in patients with idiopathic proctitis: a study to determine the active therapeutic moiety of sulphasalazine. Gut 21, 632-635 (1980)
3. Campieri M, Lanfranchi GA, Bazzocchi G, Brignola C, Sarti F, Franzin G, Battocchi A, Labo G and Dal Monte PR: Treatment of ulcerative colitis with high dose 5-aminosalicylic acid enemas. Lancet II 8, 270-271 (1981)
4. Klotz U, Maier K, Fischer C and Heinkel K: Therapeutic efficacy of sulfasalazine and its metabolites in patients with ulcerative colitis and Cronhn's disease. N Engl J Med 303, 1499-1502 (1980)
5. Das KM, Eastwood MA, McManus JPA and Sircus W: The metabolism of salicylazosulfapyridine in ulcerative colitis. Gut 14, 631-641 (1973)
6. Das KM, Eastwood MA, McManus JPA and Sircus W: Adverse reactions during salicylazosulfapyridine therapy and the relative with drug metabolism and acetylator phenotype. N Engl J Med 289, 491-495 (1973)
7. Chan RP, Pope DJ, Gilbert AP, Sacra PJ, Baron JH and Lennard-Jones JE: Studies of two novel sulfasalazine analogs, Ipsalazine and Balsalazide. Dig Dis Sci 28, 609-615 (1983)
8. Takizawa H, Shintani N, Natsui M, Sasakawa T, Nakakubo H, Nakajima T and Asakura H: Activated immunocompetent cells in rat colitis mucosal induced by dextran sulfate sodium and not complete but partial suppression of colitis by FK506. Digestion 56, 259-264 (1995)
9. MacPherson BR and Pfeiffer CJ: Experimental colitis. Digestion 14, 424-452 (1976)
10. Sharon P and Stenson WF: Metabolism of arachidonic acid colitis in rats. Gastroenterology 88, 55-63 (1985)
11. Fitzpatric LR, Bostwick JS, Renzetti M, Pendleton GR and Decktor DL: Antiinflammatory effects of various drugs on acetic acid induced colitis in the rat. Agents Actions 30, 393-402 (1990)
12. Morris GP, Beck PL, Herridge MS, Depew WTM, Szewczuk R and Wallace JL: Hapteninduced model of chronic inflammation and ulceration in the rat colon. Gastroenterology 96, 759-803 (1989)
13. Wallace JL, MacNaughton WK, Morris GP and Beck PL: Inhibition of leukotriene synthesis markedly accelerates healing in a rat model of inflammatory bowel disease. Gastroenterology 96, 29-36 (1987)
14. Rachmilewitz D, Simon PL, Schwartz LW, Griswold DE, Fondacaro JD and Wasserman MA: Inflammatory mediators of experimental colitis in rats. Gastroenterology 97, 326-337 (1987)